Cracowski J L, Marpeau C, Carpentier P H, Imbert B, Hunt M, Stanke-Labesque F, Bessard G
Grenoble University School of Medicine, France.
Arthritis Rheum. 2001 May;44(5):1143-8. doi: 10.1002/1529-0131(200105)44:5<1143::AID-ANR196>3.0.CO;2-#.
A new family of prostaglandin F2 isomers called F2-isoprostanes, produced by free radical peroxidation of arachidonic acid, has recently been described in vivo. Its quantification has been suggested to be a reliable measure of oxidant injury in vivo. The purpose of this study was to investigate urinary F2-isoprostane formation as an index of lipid peroxidation in scleroderma spectrum disorders.
Urine samples were obtained from 52 patients with systemic sclerosis (SSc; n = 37) or undifferentiated connective tissue diseases (UCTD; n = 15) and from 20 healthy volunteers. Urinary isoprostaglandin F2alpha type III (iPF2alpha-III) and 11-dehydro thromboxane B2 (11-dehydroTXB2) concentrations were determined using enzyme immunoassays.
The urinary concentration of iPF2alpha-III was approximately twice as high in patients (mean +/- SEM 229+/-16 pmoles/mmoles creatinine) as in controls (116+/-9 pmoles/mmoles creatinine) (P < 0.0001). However, the urinary concentration of iPF2alpha-III was not significantly different among patients with UCTD, limited SSc, and diffuse SSc (mean +/- SEM 221+/-27 versus 245+/-32 versus 220+/-25 pmoles/mmoles creatinine, respectively). No significant correlation was found between the urinary concentrations of iPF2alpha-III and 11-dehydroTXB2.
This study provides evidence of enhanced lipid peroxidation in both SSc and UCTD, and suggests a rationale for antioxidant treatment of SSc. Formation of F2-isoprostanes has to be investigated as a means for the evaluation of such therapy.
最近在体内发现了一类新的前列腺素F2异构体，称为F2 -异前列腺素，它是由花生四烯酸的自由基过氧化作用产生的。其定量测定被认为是体内氧化损伤的可靠指标。本研究的目的是调查尿F2 -异前列腺素的形成，作为硬皮病谱系疾病中脂质过氧化的指标。
收集了52例系统性硬化症（SSc；n = 37）或未分化结缔组织病（UCTD；n = 15）患者以及20名健康志愿者的尿液样本。使用酶免疫分析法测定尿中异前列腺素F2α III型（iPF2α-III）和11 -脱氢血栓素B2（11 -脱氢TXB2）的浓度。
患者尿中iPF2α-III的浓度（平均±标准误229±16皮摩尔/毫摩尔肌酐）约为对照组（116±9皮摩尔/毫摩尔肌酐）的两倍（P < 0.0001）。然而，UCTD、局限性SSc和弥漫性SSc患者尿中iPF2α-III的浓度无显著差异（分别为平均±标准误221±27、245±32和220±25皮摩尔/毫摩尔肌酐）。iPF2α-III和11 -脱氢TXB2的尿浓度之间未发现显著相关性。
本研究提供了SSc和UCTD中脂质过氧化增强的证据，并为SSc抗氧化治疗提供了理论依据。必须研究F2 -异前列腺素的形成作为评估此类治疗的一种手段。
